Medinol
Tel Aviv, Israel· Est.
Innovative cardiovascular device maker with CE‑approved drug‑eluting stents and emerging implantable sensor platform.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
AI Company Overview
Innovative cardiovascular device maker with CE‑approved drug‑eluting stents and emerging implantable sensor platform.
Cardiovascular
Technology Platform
Electrospinning elastomeric coating (WiZeCell™) and hybrid scaffold designs for drug‑eluting stents, plus sub‑millimeter passive implantable sensors interrogated via ultrasound.
Opportunities
Expansion of drug‑eluting stent sales into peripheral and emerging markets, commercialization of the Xemed TAVR platform, and broad adoption of implantable microsensors for heart‑failure management.
Risk Factors
Regulatory approval timelines for new devices, reimbursement challenges, and competition from established cardiovascular device giants.
Competitive Landscape
Competes with Abbott, Medtronic, and Boston Scientific in stents and TAVR, differentiating through proprietary elastomeric coatings, hybrid scaffold technology, and integrated sensor solutions.